Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

被引：0

作者：

David N. Springer

Michael Bauer

Iris Medits

Jeremy V. Camp

Stephan W. Aberle

Clemens Burtscher

Eva Höltl

Lukas Weseslindtner

Karin Stiasny

Judith H. Aberle

机构：

[1] Medical University of Vienna,Center for Virology

[2] Erste Bank,Health Center Erste Bank

[3] Medical University of Vienna,Center for Public Health

来源：

npj Vaccines | / 8卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We report SARS-CoV-2 neutralizing antibody titers in sera of triple-vaccinated individuals who received a booster dose of an original monovalent or a bivalent BA.1- or BA.4/BA.5-adapted vaccine or had a breakthrough infection with Omicron variants BA.1, BA.2 or BA.4/BA.5. A bivalent BA.4/BA.5 booster or Omicron-breakthrough infection induced increased Omicron-neutralization titers compared with the monovalent booster. The XBB.1.5 variant effectively evaded neutralizing-antibody responses elicited by current vaccines and/or infection with previous variants.

引用

共 50 条

[21] Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination
Yuag-Meng Liu
Yu-Lin Lee
Chun-Eng Liu
Yi-Chun Chen
Ni Tien
Wen-Chi Su
Infection, 2023, 51 : 531 - 534
[22] Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States
Di Fusco, Manuela
Marczell, Kinga
Thoburn, Elizabeth
Wiemken, Timothy. L. L.
Yang, Jingyan
Yarnoff, Benjamin
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 509 - 524
[23] Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods
Link-Gelles, Ruth
Levy, Matthew E.
Natarajan, Karthik
Reese, Sarah E.
Naleway, Allison L.
Grannis, Shaun J.
Klein, Nicola P.
DeSilva, Malini B.
Ong, Toan C.
Gaglani, Manjusha
Hartmann, Emily
Dickerson, Monica
Stenehjem, Edward
Kharbanda, Anupam B.
Han, Jungmi
Spark, Talia L.
Irving, Stephanie A.
Dixon, Brian E.
Zerbo, Ousseny
McEvoy, Charlene E.
Rao, Suchitra
Raiyani, Chandni
Sloan-Aagard, Chantel
Patel, Palak
Dascomb, Kristin
Uhlemann, Anne-Catrin
Dunne, Margaret M.
Fadel, William F.
Lewis, Ned
Barron, Michelle A.
Murthy, Kempapura
Nanez, Juan
Griggs, Eric P.
Grisel, Nancy
Annavajhala, Medini K.
Akinseye, Akintunde
Valvi, Nimish R.
Goddard, Kristin
Mamawala, Mufaddal
Arndorfer, Julie
Yang, Duck-Hye
Embi, Peter J.
Fireman, Bruce
Ball, Sarah W.
Tenforde, Mark W.
JAMA NETWORK OPEN, 2023, 6 (03) : E232598
[24] What Omicron’s BA.4 and BA.5 variants mean for the pandemic
Ewen Callaway
Nature, 2022, 606 : 848 - 849
[25] Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Tseng, Hung Fu
Ackerson, Bradley K.
Bruxvoort, Katia J.
Sy, Lina S.
Tubert, Julia E.
Lee, Gina S.
Ku, Jennifer H.
Florea, Ana
Luo, Yi
Qiu, Sijia
Choi, Soon Kyu
Takhar, Harpreet S.
Aragones, Michael
Paila, Yamuna D.
Chavers, Scott
Talarico, Carla A.
Qian, Lei
NATURE COMMUNICATIONS, 2023, 14 (01)
[26] Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Hung Fu Tseng
Bradley K. Ackerson
Katia J. Bruxvoort
Lina S. Sy
Julia E. Tubert
Gina S. Lee
Jennifer H. Ku
Ana Florea
Yi Luo
Sijia Qiu
Soon Kyu Choi
Harpreet S. Takhar
Michael Aragones
Yamuna D. Paila
Scott Chavers
Carla A. Talarico
Lei Qian
Nature Communications, 14
[27] Heterologous booster vaccines reduce severity and mortality in COVID-19 during BA.2 and BA.4/BA.5 omicron predominance in Thailand
Intawong, Kannikar
Chariyalertsak, Suwat
Chalom, Kittipan
Wonghirundecha, Thanachol
Kowatcharakul, Woravut
Thongprachum, Aksara
Chotirosniramit, Narain
Noppakun, Kajohnsak
Khwanngern, Krit
Teacharak, Worachet
Piamanant, Prapon
Khammawan, Pimpinan
Iamsirithaworng, Sopon
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2023, 56 (06) : 1178 - 1186
[28] Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1)
Goh, Yun Shan
Fong, Siew-Wai
Hor, Pei Xiang
Loh, Chiew Yee
Tay, Matthew Zirui
Wang, Bei
Salleh, Siti Nazihah Mohd
Ngoh, Eve Zi Xian
Lee, Raphael Tze Chuen
Poh, Xuan Ying
Lee, I. Russel
Rao, Suma
Chia, Po Ying
Maurer-Stroh, Sebastian
Wang, Cheng-, I
Leo, Yee-Sin
Lye, David C.
Young, Barnaby Edward
Ng, Lisa F. P.
Renia, Laurent
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 146
[29] Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
Zaeck, Luca M.
Tan, Ngoc H.
Rietdijk, Wim J. R.
Geers, Daryl
Sablerolles, Roos S. G.
Bogers, Susanne
van Dijk, Laura L. A.
Gommers, Lennert
van Leeuwen, Leanne P. M.
Rugebregt, Sharona
Goorhuis, Abraham
Postma, Douwe F.
Visser, Leo G.
Dalm, Virgil A. S. H.
Lafeber, Melvin
Kootstra, Neeltje A.
Huckriede, Anke L. W.
Haagmans, Bart L.
van Baarle, Debbie
Koopmans, Marion P. G.
van der Kuy, P. Hugo M.
Geurtsvankessel, Corine H.
de Vries, Rory D.
NATURE COMMUNICATIONS, 2024, 15 (01) : 4224
[30] Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccineexperienced humans and mice
Muik, Alexander
Lui, Bonny Gaby
Bacher, Maren
Wallisch, Ann-Kathrin
Toker, Aras
Couto, Carla Iris Cadima
Gueler, Alptekin
Mampilli, Veena
Schmitt, Geneva J.
Mottl, Jonathan
Ziegenhals, Thomas
Fesser, Stephanie
Reinholz, Jonas
Wernig, Florian
Schraut, Karla-Gerlinde
Hefesha, Hossam
Cai, Hui
Yang, Qi
Walzer, Kerstin C.
Grosser, Jessica
Strauss, Stefan
Finlayson, Andrew
Kruger, Kimberly
Ozhelvaci, Orkun
Grikscheit, Katharina
Kohmer, Niko
Ciesek, Sandra
Swanson, Kena A.
Vogel, Annette B.
Tuereci, Oezlem
Sahin, Ugur
SCIENCE IMMUNOLOGY, 2022, 7 (78)

← 1 2 3 4 5 →